Next Science Limited
NXSCF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $10 | $12 | $11 | $13 |
| % Growth | -9.4% | 3.1% | -10.8% | – |
| Cost of Goods Sold | $2 | $2 | $2 | $3 |
| Gross Profit | $9 | $9 | $9 | $9 |
| % Margin | 83.2% | 81.9% | 79.8% | 73.1% |
| R&D Expenses | $3 | $3 | $3 | $3 |
| G&A Expenses | $4 | $4 | $3 | $3 |
| SG&A Expenses | $10 | $11 | $12 | $14 |
| Sales & Mktg Exp. | $7 | $7 | $9 | $11 |
| Other Operating Expenses | -$0 | -$0 | -$0 | $0 |
| Operating Expenses | $13 | $14 | $15 | $17 |
| Operating Income | -$4 | -$4 | -$6 | -$8 |
| % Margin | -41.2% | -38.4% | -52.2% | -64.3% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$5 | -$5 | -$6 | -$8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$5 | -$6 | -$8 |
| % Margin | -44.7% | -41% | -52% | -63.5% |
| EPS | -0.016 | -0.016 | -0.03 | -0.031 |
| % Growth | 1.8% | 45.7% | 2.3% | – |
| EPS Diluted | -0.016 | -0.016 | -0.03 | -0.031 |
| Weighted Avg Shares Out | 292 | 291 | 292 | 260 |
| Weighted Avg Shares Out Dil | 292 | 292 | 292 | 260 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | -$4 | -$4 | -$5 | -$7 |
| % Margin | -39% | -35.6% | -46.8% | -55.5% |